Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-10, Vol.14
Main Authors: Mutlu, Yasa Gul, Yıgıt Kaya, Sureyya, Maral, Senem, Melek, Elif, Baslar, Zafer, Kaynar, Leylagul, Sevindik, Omur Gokmen
Format: Article
Language:English
Subjects:
BCMA
bispecific Ab
CNS involvement
Elranatamab
Immunology
multiple myeloma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1276295